We have a suspicion that you are an automated web bot software, not a real user. To keep our site fast for other users, we have slowed down this page. The slowdown will gradually disappear. If you think this is a mistake, please contact us at genome-www@soe.ucsc.edu. Also note that all data for hgGeneGraph can be obtained through our public MySQL server and all our software source code is available and can be installed locally onto your own computer. If you are unsure how to use these resources, do not hesitate to contact us.
UCSC Genome Browser Gene Interaction Graph
Gene interactions and pathways from curated databases and text-mining

◀ Back to MTOR

IL10 — MTOR

Text-mined interactions from Literome

Ohtani et al., Blood 2008 (Leishmaniasis, Cutaneous) : Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide induced interleukin-12 production in dendritic cells
Weichhart et al., Immunity 2008 (Inflammation...) : Inhibition of mTOR by rapamycin promoted production of proinflammatory cytokines via the transcription factor NF-kappaB but blocked the release of interleukin-10 via the transcription factor STAT3
Baker et al., Mol Immunol 2009 : The results indicate that mTOR dependent IL-10 expression leads to inhibition of LPS induction of TF and the proinflammatory cytokine TNFalpha in WT macrophages
Cheekatla et al., Med Microbiol Immunol 2012 (Leishmaniasis, Visceral) : We show for the first time that in THP-1 derived macrophages and human monocytes, mTOR inhibition by rapamycin reversed L. donovani induced IL-12 and IL-10 modulation
Foldenauer et al., J Immunol 2013 (Keratitis...) : Because the mammalian target of rapamycin (mTOR) regulates IL-10 in other disease models, the present study tested its role in bacterial keratitis ... Collectively, these data, as well as a rescue experiment using rIL-10 together with rapamycin, which decreased PMN in cornea, provide concrete evidence that mTOR regulates IL-10 in P. aeruginosa induced bacterial keratitis and is critical to balancing pro- and anti-inflammatory events, resulting in better disease outcome